Glioblastoma in Réunion: an epidemiological and socio-anthropological look at patients and care

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a mixed-methods study that combines retrospective and prospective data collection on adults with incident diffuse gliomas diagnosed since 2018 in Réunion. The project uses epidemiological data plus qualitative interviews to explore socio-cultural factors, care pathways, and patient experiences. Data will come from medical records and direct interviews with patients and healthcare professionals, aiming to map population characteristics, treatment patterns, and gaps in care. The study is led by the Centre Hospitalier Universitaire de la Réunion and involves collaboration with local clinicians and researchers. No interventional procedures are involved; the focus is observational and descriptive.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Quantitative study (retrospective and prospective components):

Patients aged 18 and over:

* With a histological diagnosis of incident diffuse glioma since January 1, 2018
* Residing in Réunion at the time of diagnosis,
* Having been informed about the study procedures
* Having agreed to participate in the study

Socio-anthropological study (prospective component):

Patients:

* Meeting the inclusion criteria for the prospective quantitative study and agreeing to participate in the qualitative component,
* Speaking French. • Able to participate in a face-to-face interview

Healthcare Professional:

* Professionals involved in the care of patients with brain tumors (medical, paramedical, social care, support care, etc.) who have agreed to participate in the study
* The healthcare professionals concerned will be general practitioners, neurosurgeons, neurologists, radiation oncologists, medical oncologists, home healthcare physicians, palliative care physicians, pathologists, nurses responsible for diagnosis and follow-up, psychologists, social workers, and dietitians.

Exclusion Criteria:

Regarding the quantitative study:

Patient:

Refusing to participate in the quantitative study Having a recurrent diffuse glioma Person deprived of their liberty and judgment by judicial or administrative decision, and person subject to a legal protection measure: guardianship or curatorship, under judicial protection, under legal guardianship, etc.)

Regarding the socio-anthropological study:

Patient:

Refusing to participate in the qualitative study Does not speak French Having serious somatic or mental health problems incompatible with the interview Healthcare professionals: Refusing to participate in the study

Where it's running

• Mélanie BEGORRE
  Saint-Pierre, Reunion Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• YN003 injection in glioma patients

  This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.

  Recruiting at 2 sites Phase 1 Beijing Inno Medicine Co., Ltd. · Los Angeles, California and 4 other locations · NCT07929909

• Brain connectome project in adults with brain glioma undergoing surgery

  This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.

  Recruiting Northwell Health · New York, New York · NCT07927595

• Lixumistat window of opportunity in newly diagnosed glioblastoma

  This study tests whether Lixumistat can benefit adults with newly diagnosed glioblastoma who are planned for surgical tumor removal.

  Recruiting Early Phase 1 University of Miami · Miami, Florida · NCT07884344

• Butterfly glioblastoma: test adding 5-ALA PoMA with LIDU ultrasound to standard care

  This early-phase study tests whether adding 5-ALA–mediated activation with LIDU ultrasound is safe and tolerable for adults with newly diagnosed butterfly glioblastoma, before or during standard chemotherapy and radiotherapy.

  Recruiting Phase 1 Alpheus Medical, Inc. · Buffalo, New York · NCT07862647

• Maintenance radiotherapy after standard glioblastoma treatment

  This study tests whether a single 2 Gy maintenance radiotherapy dose after standard treatment is safe and feasible for adults with newly diagnosed glioblastoma.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07831772

• Valproic acid, irinotecan, and simvastatin for recurrent glioma in adults

  This trial tests whether the combination of valproic acid, irinotecan, and simvastatin can stabilize or shrink recurrent glioblastoma or IDH-mutant gliomas in adults.

  Recruiting Phase 2 Inova Health Care Services · Fairfax, Virginia · NCT07831369

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.